Information  X 
Enter a valid email address

Astrazeneca PLC Ord (AZN)

Date Time Source Announcement
16 Aug 2022 7:00 am
RNS
Lynparza granted FDA priority review for PROpel
15 Aug 2022 7:00 am
RNS
Enhertu improved PFS in mBC in DESTINY-Breast02
12 Aug 2022 7:00 am
RNS
Enhertu approved in US for HER2-mutant NSCLC
11 Aug 2022 7:00 am
RNS
Acquisition of TeneoTwo completed
08 Aug 2022 7:10 am
RNS
Enhertu approved in the US for HER2-low mBC
04 Aug 2022 7:00 am
RNS
Lynparza approved in EU for early breast cancer
01 Aug 2022 5:00 pm
RNS
Director/PDMR Shareholding
  3:05 pm
RNS
Director/PDMR Shareholding
  3:00 pm
RNS
Total Voting Rights
29 Jul 2022 7:01 am
RNS
Chair succession
  7:00 am
RNS
Half-year Report
25 Jul 2022 7:10 am
RNS
Tezspire recommended for EU approval in asthma
  7:05 am
RNS
Ultomiris recommended for EU approval for gMG
  7:00 am
RNS
Enhertu granted Priority Review for HER2-low mBC
19 Jul 2022 7:00 am
RNS
Enhertu approved in EU for HER2-positive mBC
05 Jul 2022 7:00 am
RNS
AstraZeneca to acquire TeneoTwo and T cell engager
01 Jul 2022 3:00 pm
RNS
Total Voting Rights
30 Jun 2022 7:00 am
RNS
Imfinzi improved pCR in resectable lung cancer
27 Jun 2022 7:05 am
RNS
Enhertu recommended for breast cancer EU approval
  7:00 am
RNS
Lynparza recommended in EU for early breast cancer
21 Jun 2022 7:00 am
RNS
Eplontersen Ph III trial met co-primary endpoints
06 Jun 2022 7:00 am
RNS
Enhertu efficacy results in HER2-low breast cancer
01 Jun 2022 3:00 pm
RNS
Block listing Interim Review
  3:00 pm
RNS
Total Voting Rights
20 May 2022 4:00 pm
RNS
Director/PDMR Shareholding
09 May 2022 1:00 pm
RNS
Appointment of joint corporate brokers
06 May 2022 4:00 pm
RNS
Director/PDMR Shareholding
05 May 2022 7:10 am
RNS
Enhertu approved in US for 2L HER2+ breast cancer
  7:05 am
RNS
Farxiga HFpEF Phase III trial met primary endpoint
  7:00 am
RNS
Ultomiris NMOSD Ph. III trial met primary endpoint
04 May 2022 7:00 am
RNS
Imfinzi combo granted Priority Review for BTC
03 May 2022 3:00 pm
RNS
Total Voting Rights
29 Apr 2022 5:30 pm
RNS
Result of AGM
  7:05 am
RNS
AstraZeneca plans new R&D centre in Massachusetts
  7:00 am
RNS
First quarter 2022 results
28 Apr 2022 7:00 am
RNS
Ultomiris approved in the US for adults with gMG
27 Apr 2022 7:00 am
RNS
Enhertu granted BTD for HER2-low breast cancer
25 Apr 2022 7:00 am
RNS
Tremelimumab US Priority Review for Imfinzi combo
19 Apr 2022 7:00 am
RNS
Enhertu granted Priority Review for HER2m NSCLC
01 Apr 2022 3:00 pm
RNS
Total Voting Rights
29 Mar 2022 7:00 am
RNS
Ondexxya approved in Japan for FXai reversal
28 Mar 2022 7:00 am
RNS
Evusheld approved in the EU for COVID-19
25 Mar 2022 3:30 pm
RNS
Director/PDMR Shareholding
24 Mar 2022 6:00 pm
RNS
Evusheld Positive EU CHMP Opinion
  7:00 am
RNS
Update on CALLA Phase III trial for Imfinzi
23 Mar 2022 11:00 am
RNS
Notice of AGM
17 Mar 2022 7:00 am
RNS
Settlement of patent litigation for Ultomiris
14 Mar 2022 7:05 am
RNS
Lynparza approved in US for early breast cancer
  7:00 am
RNS
Update on US review of Fasenra in nasal polyps
09 Mar 2022 3:30 pm
RNS
Director/PDMR Shareholding
07 Mar 2022 3:30 pm
RNS
Director/PDMR Shareholding
01 Mar 2022 3:30 pm
RNS
Director/PDMR Shareholding
  3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
AstraZeneca and Neurimmune close deal for NI006
23 Feb 2022 7:00 am
RNS
Filing of Form 20-F with SEC
22 Feb 2022 11:00 am
RNS
Chair succession planning update and Annual Report
21 Feb 2022 7:00 am
RNS
Enhertu improves PFS and OS in HER2-low BC
16 Feb 2022 7:00 am
RNS
Saphnelo approved in EU for SLE
15 Feb 2022 7:00 am
RNS
Lynparza combo delays progression risk in prostate
11 Feb 2022 3:30 pm
RNS
Director/PDMR Shareholding

a d v e r t i s e m e n t